$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[미국특허] Adjuvant therapy with an anti-ERBB2 antibody conjugated to a maytansiniod 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-039/395
출원번호 US-0205523 (2011-08-08)
등록번호 US-8597654 (2013-12-03)
발명자 / 주소
  • Bryant, John L.
출원인 / 주소
  • Genentech, Inc.
대리인 / 주소
    Pasqualone, Danielle
인용정보 피인용 횟수 : 5  인용 특허 : 84

초록

The present application describes adjuvant therapy of nonmetastatic breast cancer using an anti-ErbB2 antibody conjugated to a maytansinoid.

대표청구항

1. A method of adjuvant therapy comprising administering to a human subject having HER2 positive cancer, following definitive surgery, anthracycline cyclophosphamide (AC) based chemotherapy, followed by sequential administration of a taxoid and an effective amount of an immunoconjugate comprising an

이 특허에 인용된 특허 (84) 인용/피인용 타임라인 분석

  1. King C. Richter (Washington DC) Kasprzyk Philip G. (Washington DC) Bird Robert E. (Rockville MD), Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof.
  2. Shawver Laura K. ; Brandis John W. ; Mann Elaina ; Hancock Miriam E. C. ; Mischak Ronald P. ; Monahan John J., Anti-neoplastic drugs in cancer therapy.
  3. Ebens, Jr., Allen J.; Jacobson, Frederic S.; Polakis, Paul; Schwall, Ralph H.; Sliwkowski, Mark X.; Spencer, Susan D., Antibody-drug conjugates and methods.
  4. Arakawa Tsutomu ; Kita Yoshiko, Antibody-induced apoptosis.
  5. Tsutomu Arakawa ; Yoshiko Kita, Antibody-induced apoptosis.
  6. Plowman Gregory D., Assay for agents active in proliferative disorders.
  7. Ross Jeffrey S. ; Muraca Patrick J., Assessment of prostate cancer.
  8. Blättler, Walter A.; Chari, Ravi V. J., Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents.
  9. Chari, Ravi V. J., Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents.
  10. Chari,Ravi V. J., Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents.
  11. Huston James S. ; Houston L. L. ; Ring David B. ; Oppermann Hermann, DNA encoding biosynthetic binding protein for cancer marker.
  12. Kraus Matthias H. (Bethesda MD) Aaronson Stuart A. (Vienna VA), DNA segment encoding a gene for a receptor related to the epidermal growth factor receptor.
  13. Carney Walter P. (North Andover MA) McKenzie Sara J. (Lynn MA), Detection and quantification of neu related proteins in the biological fluids of humans.
  14. Carney, Walter P.; McKenzie, Sara J.; Weinberg, Robert A., Detection of neu p185 in cell lysates.
  15. Bargmann Cornelia I. (Arlington MA) Weinberg Robert A. (Brookline MA), Detection of point mutations in neu genes.
  16. Slamon Dennis J. (Woodland Hills CA) McGuire William L. (San Antonio TX), Determination of status in neoplastic disease.
  17. Baughman, Sharon A.; Shak, Steven, Dosages for treatment with anti-ErbB2 antibodies.
  18. Carter Paul J. (San Francisco CA), Expression of functional antibody fragments.
  19. Jensen Ronald H. ; Cher Michael L., Genetic alterations associated with prostate cancer.
  20. Slamon, Dennis J.; Wilson, Cindy A.; Calzone, Frank J., HER-2/neu overexpression abrogates growth inhibitory pathways.
  21. Hudziak Robert Michael ; Shepard H. Michael ; Ullrich Axel, HER2 extracellular domain.
  22. Hudziak Robert Michael ; Shepard H. Michael ; Ullrich Axel,DEX, HER2 extracellular domain.
  23. Marks James D. ; Schier Robert, High affinity human antibodies to tumor antigens.
  24. Marks, James D.; Schier, Robert, High affinity human antibodies to tumor antigens.
  25. Carter Paul J. ; Presta Leonard G., Humanized antibodies and methods for making them.
  26. Carter Paul J. ; Presta Leonard G., Immunoglobulin variants.
  27. Benz Christopher C. ; Papahadjopoulos Demetrios P. ; Park John W. ; Hong Keelung ; Kirpotin Dmitri, Immunoliposomes that optimize internalization into target cells.
  28. Hudziak Robert M. ; Ullrich Axel ; Fendly Brian M., In vivo tumor detection assay.
  29. Kraus Matthias H. (Bethesda MD) Aaronson Stuart A. (Vienna VA), Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto.
  30. Deborah R. Jaffee ; Kerry J. Flom, Method and kit for the prognostication of breast cancer.
  31. Carter, Paul J.; Presta, Leonard G., Method for making humanized antibodies.
  32. Carter, Paul J.; Presta, Leonard G., Method for making humanized antibodies.
  33. Paul J. Carter ; Leonard G. Presta, Method for making humanized antibodies.
  34. Bacus Sarah S. (Hinsdale IL), Method for prognosticating response to cancer therapy.
  35. Vandlen Richard L. (Hillsborough CA) Holmes William E. (Pacifica CA), Method for purifying heregulin.
  36. Wang Mary Ge ; George ; Jr. Albert Louis ; Light Elizabeth Sophia, Method for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue.
  37. Danenberg, Kathleen D., Method of determining a chemotherapeutic regimen based on ERCC1 expression.
  38. Danenberg, Kathleen D., Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates.
  39. Steeves, Rita M.; Chari, Ravi V. J.; Blattler, Walter A., Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates.
  40. Steeves, Rita M.; Chari, Ravi V. J.; Blattler, Walter A., Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates.
  41. Steeves, Rita M.; Chari, Ravi V. J.; Blattler, Walter A., Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates.
  42. Steeves, Rita M.; Chari, Ravi V. J.; Blättler, Walter A., Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates.
  43. Bacus Sarah S. (Hinsdale IL), Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy.
  44. Koski Raymond A., Methods and compositions for determining HER-2/neu expression using monoclonal antibodies.
  45. Curiel David T. ; Deshane Jessy, Methods for modulating protein function in cells using intracellular antibody homologues.
  46. Curiel David T. ; Deshane Jessy, Methods for modulating protein function in cells using, intracellular antibody homologues.
  47. Greene Mark I., Methods of treating cancerous cells with anti-receptor antibodies.
  48. Blättler, Walter; Chari, Ravi V. J., Methods of treatment using anti-ERBB antibody-maytansinoid conjugates.
  49. Erickson, Sharon; Schwall, Ralph; Sliwkowski, Mark; Blattler, Walter, Methods of treatment using anti-ErbB antibody-maytansinoid conjugates.
  50. Erickson,Sharon; Schwall,Ralph; Sliwkowski,Mark; Blattler,Walter, Methods of treatment using anti-ErbB antibody-maytansinoid conjugates.
  51. Hudziak Robert M. (Corvallis OR) Shepard H. Michael (Rancho Santa Fe CA) Ullrich Axel (Portola Valley CA) Fendly Brian M. (Half Moon Bay CA), Monoclonal antibodies directed to the HER2 receptor.
  52. Hudziak Robert M. ; Shepard H. Michael ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the HER2 receptor.
  53. Hudziak Robert M. ; Shepard H. Michael ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the HER2 receptor.
  54. Hudziak Robert M. ; Shepard H. Michael ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the HER2 receptor.
  55. Hudziak Robert M. ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the HER2 receptor.
  56. Robert M. Hudziak ; H. Michael Shepard ; Axel Ullrich ; Brian M. Fendly, Monoclonal antibodies directed to the HER2 receptor.
  57. Robert M. Hudziak ; H. Michael Shepard ; Axel Ullrich ; Brian M. Fendly, Monoclonal antibodies directed to the HER2 receptor.
  58. Hudziak Robert M. ; Shepard H. Michael ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the her2 receptor.
  59. Greene, Mark I.; Katsumato, Makoto, Prevention of tumors with monoclonal antibodies against neu.
  60. Andya James ; Cleland Jeffrey L. ; Hsu Chung C. ; Lam Xanthe M. ; Overcashier David E. ; Shire Steven J. ; Yang Janet Yu-Feng ; Wu Sylvia Sau-Yan, Protein formulation.
  61. Andya, James; Cleland, Jeffrey L.; Hsu, Chung C.; Lam, Xanthe M.; Overcashier, David E.; Shire, Steven J.; Yang, Janet Yu-Feng; Wu, Sylvia Sau-Yan, Protein formulation.
  62. Cleland, Jeffrey L.; Hsu, Chung C.; Lam, Xanthe M.; Overcashier, David E.; Yang, Janet Yu-Feng, Protein formulation.
  63. Blank Gregory S., Protein purification.
  64. Blank, Gregory S., Protein purification.
  65. Carol D. Basey ; Greg S. Blank, Protein purification.
  66. Carol D. Basey ; Greg S. Blank, Protein purification.
  67. Carol D. Basey ; Greg S. Blank, Protein purification.
  68. Blank Gregory S., Protein purification by Protein A chromatography.
  69. King C. Richter ; Kraus Matthias H. ; Aaronson Stuart A., Protein related to but distinct from EGF receptor and antibodies reactive therewith.
  70. Slamon Dennis J. ; Press Michael F., Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination.
  71. Wels Winfried S. (Basel CHX) Hynes Nancy E. (Basel CHX) Harweth Ina-Maria (Grenzach-Wyhlen DEX) Groner Bernd (Basel CHX) Hardman Norman (Riehen CHX) Zwickl Markus (Basel CHX), Recombinant antibodies specific for a growth factor receptor.
  72. Wels Winfried Stephan,CHX ; Hynes Nancy E.,CHX ; Harwerth Ina-Maria,DEX ; Groner Bernd,CHX ; Hardman Norman,CHX ; Zwickl Markus,CHX, Recombinant antibodies specific for a growth factor receptor.
  73. Erickson, Sharon; King, Kathleen; Schwall, Ralph, Rodent HER2 tumor model.
  74. Deo Yashwant M. ; Goldstein Joel ; Graziano Robert ; Somasundaram Chezian, Therapeutic compounds comprised of anti-Fc receptor antibodies.
  75. Deo Yashwant M. ; Goldstein Joel ; Graziano Robert ; Somasundaram Chezian, Therapeutic compounds comprised of anti-Fc receptor antibodies.
  76. Yashwant M. Deo ; Joel Goldstein ; Robert Graziano ; Chezian Somasundaram, Therapeutic compounds comprised of anti-Fc receptor antibodies.
  77. Deo Yashwant M. ; Graziano Robert ; Keler Tibor, Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies.
  78. Cohen, Robert L.; Gardiner, Mary Beth; Sliwkowski, Mark X.; Stelzer, Gregory T., Tissue analysis and kits therefor.
  79. Andrew J. Dannenberg ; Kotha Subbaramaiah, Treating cancers associated with overexpression of HER-2/neu.
  80. Greene Mark I. ; Drebin Jeffrey A., Treatment of tumors with monoclonal antibodies against oncogene antigens.
  81. Adams,Camellia W.; Presta,Leonard G.; Sliwkowski,Mark, Treatment with anti-ErbB2 antibody combinations.
  82. Vogel Charles L. ; Bellet Robert E., Use of docetaxel for treating cancers.
  83. Shawver, Laura K.; Brandis, John W.; Mann, Elaina; Hancock, Miriam E.C.; Mischak, Ronald P.; Monahan, John J., Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy.
  84. King C. Richter ; Kraus Matthias H. ; Aaronson Stuart A., erbB-2 gene segments, probes, recombinant DNA and kits for detection.

이 특허를 인용한 특허 (5) 인용/피인용 타임라인 분석

  1. Harris, Reed J.; Motchnik, Paul A., Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof.
  2. Andya, James; Gwee, Shiang C.; Liu, Jun; Shen, Ye, Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody.
  3. Gennaro, Lynn A.; Kao, Yung-Hsiang; Zhang, Yonghua, Pertuzumab variants and evaluation thereof.
  4. Gennaro, Lynn A.; Kao, Yung-Hsiang; Zhang, Yonghua, Pertuzumab variants and evaluation thereof.
  5. Amler, Lukas C.; Birkner, Merrill; Lin, Chin-Yu; Moecks, Joachim; Strauss, Andreas, Predicting response to a HER inhibitor.

활용도 분석정보

상세보기
다운로드
내보내기

활용도 Top5 특허

해당 특허가 속한 카테고리에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로